Your browser doesn't support javascript.
loading
Antipsychotic-induced Tardive dyskinesia: from biological basis to clinical management.
Salem, Haitham; Pigott, Teresa; Zhang, Xiang Y; Zeni, Cristian P; Teixeira, Antonio L.
Afiliación
  • Salem H; a Harris County psychiatric center, Department Psychiatry and behavioral sciences, McGovern medical school , The university of texas health science center at Houston , TX , USA.
  • Pigott T; b Neuropsychiatry program, Department Psychiatry and behavioral sciences, McGovern medical school , The university of texas health science center at Houston , TX , USA.
  • Zhang XY; a Harris County psychiatric center, Department Psychiatry and behavioral sciences, McGovern medical school , The university of texas health science center at Houston , TX , USA.
  • Zeni CP; b Neuropsychiatry program, Department Psychiatry and behavioral sciences, McGovern medical school , The university of texas health science center at Houston , TX , USA.
  • Teixeira AL; c Pediatric mood disorder/ADHD program, Department Psychiatry and behavioral sciences, McGovern medical school , The university of texas health science center at Houston , TX , USA.
Expert Rev Neurother ; 17(9): 883-894, 2017 Sep.
Article en En | MEDLINE | ID: mdl-28750568
ABSTRACT

INTRODUCTION:

Tardive dyskinesia (TD) is a chronic and disabling movement disorder with a complex pathophysiological basis. A significant percentage of patients does not receive correct diagnosis, resulting in delayed or inaccurate treatment and poor outcome. Therefore, there is a critical need for prompt recognition, implementation of efficacious treatment regimens and long-term follow up of patients with TD. Areas covered The current paper provides an overview of emerging data concerning proposed pathophysiology theories, epidemiology, risk factors, and therapeutic strategies for TD. Expert commentary Despite considerable research efforts, TD remains a challenge in the treatment of psychosis as the available strategies remain sub-optimal. The best scenario will always be the prophylaxis or prevention of TD, which entails limiting the use of antipsychotics.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trastornos Psicóticos / Esquizofrenia / Antipsicóticos / Agonistas del GABA / Antagonistas Colinérgicos / Adrenérgicos / Estimulación Encefálica Profunda / Proteínas de Transporte Vesicular de Monoaminas / Discinesia Tardía Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Expert Rev Neurother Asunto de la revista: NEUROLOGIA / TERAPEUTICA Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: ENGLAND / ESCOCIA / GB / GREAT BRITAIN / INGLATERRA / REINO UNIDO / SCOTLAND / UK / UNITED KINGDOM

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trastornos Psicóticos / Esquizofrenia / Antipsicóticos / Agonistas del GABA / Antagonistas Colinérgicos / Adrenérgicos / Estimulación Encefálica Profunda / Proteínas de Transporte Vesicular de Monoaminas / Discinesia Tardía Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Expert Rev Neurother Asunto de la revista: NEUROLOGIA / TERAPEUTICA Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: ENGLAND / ESCOCIA / GB / GREAT BRITAIN / INGLATERRA / REINO UNIDO / SCOTLAND / UK / UNITED KINGDOM